Sirna Therapeutics and Invitrogen and DNA Research Innovations

Nov 05, 2004

Premium

Sirna Reports 70-percent drop in Q3 Revenues

Sirna Therapeutics reported last week its financial results for the third quarter 2004, posting a sharp drop off in revenues amid a decline in expenses.

Sirna’s revenues for the third quarter were $84,000, compared with $283,000 in the year-ago period. The company attributed the 70 percent decline to the completion of ribozyme-related manufacturing programs as its new aptamer manufacturing arrangement with Archemix gets underway.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Featured White Papers

Controlling Ribonuclease (RNase) with High Irradiance UV LED Light Engines

The Ultimate Guide to Mouse Clinical Trials

High Throughput RT-qPCR for Gene Expression Analysis

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Main menu